GlobeNewswire

Axiom Real-Time Metrics Receives Investment from Great Point Partners

Share

TORONTO, May 08, 2019 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services, today announces significant strategic growth funding.  The investment has been led by Great Point Partners (“GPP”), a leading health care investment firm with approximately $1.6 billion of equity capital currently under management. 

This event marks a significant milestone for Axiom, which was founded in 2001.  Axiom, an established player in the eClinical market, is unique in its position in this space, as its significant growth has been accomplished through reinvestment of revenue, rather than through external investment.  A strategic and pivotal decision for the organization, the collaboration with GPP represents the first investment of outside capital that Axiom has taken on. 

The investment by GPP will position Axiom to accelerate the development and addition of leading-edge elements to its Fusion eClinical platform.  Additionally, funds will be utilized to significantly expand professional services and business development initiatives.

“Our decision to work with Great Point Partners is based on our synergies, their hyper-focused area of life sciences, and the deep understanding of the space that they bring to the table.  We are thrilled to be bringing onboard our first investment into Axiom with a group of their caliber”, shared Andrew Schachter, Founder and CEO.

Axiom is currently the leading provider of eClinical software and associated services to small to medium sized life sciences companies.  It’s eClinical suite, Fusion, is enterprise level in its depth and scope, with all of its technology developed in-house.  A key message of Axiom “We think differently”, is delivered upon through powerful, flexible and tailored solutions , priced to suit the needs of this small to medium-sized market, and providing service and a level of dedication in its client partnerships that is unmatched.

Andrew Schachter, Founder and CEO, continued, “I am very excited about GPP’s investment into Axiom that we are announcing today.  Axiom has experienced tremendous continued growth over the past several years.  My team and I have grown the company for over 18 years without taking external capital to date.  We have built the Fusion eClinical Suite into the world class leading enterprise platform for EDC, IWRS, ePRO and CTMS operations focused on small to medium life sciences.  As we continue to expand, this investment will augment innovation and resources for the breadth and depth of the Fusion platform, its modules and the accompanying services we wrap around them.  We have a lot of exciting technologies and features to be released over the next few quarters to share with our clients.”

About Axiom Real-Time Metrics

Headquartered in Toronto, Canada, Axiom delivers intuitive, powerful and cost-effective eClinical solutions and services focused around your entire study.  Services include: Data Management, Data Analytics, Biostatistics and Pharmacovigilance.  Axiom's eClinical suite, Fusion, delivers a powerful range of innovative end-user focused, unified functionality and 15 modules.  Axiom serves as the Connected Hub for your entire clinical study data and operational needs.  Fusion Delivers: EDC, DM, IWRS, CTMS, Inventory Management, IVR, Patient Portal, AE/SAE Tracking, Safety Database, Central Lab, Imaging, eTMF, and 24/7 Project and Clinical Data Reporting.  For more information, please visit http://www.axiommetrics.com/.

Contact
solutions@axiom.cc +1.877.321.9191

PR Contact
Sarah Glofcheskie
sarahg@axiom.cc +1.647.588.9073

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.5 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe.  GPP is currently making new private equity investments from GPP II, which closed on $215 million.  Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III which has over $280 million in committed capital) and public (BioMedical Value Fund, approximately $1.1 billion) equity funds.  Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies.  The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses.  The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.  Reach Great Point at 203-971-3300 or www.gppfunds.com

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPress release

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPressemelding

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Nexstim reports good initial results on the use of Smartfocus® technology in treatment of major depressive disorder20.8.2019 09:00:00 CESTPress release

Press Release, Helsinki, 20 August 2019 at 10.00 am (EET) Nexstim reports good initial results on the use of Smartfocus ® technology in treatment of major depressive disorder Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and marketing a unique brain stimulation technology for personalized treatment of major depressive disorder (MDD) – announces that the first white paper about the initial experiences of its NBT® system with SmartFocus® technology in treatment of MDD has been published. The white paper is published by Island Psychiatry PC, a New York -based TMS therapy provider and Nexstim. It reports the experiences in the first 10 consecutive patients completing treatment of MDD with Nexstim NBT® system at Island Psychiatry’s clinic. The treatment outcomes of these 10 adult patients were good. 50 % of the patients were in remission at the end of the treatment while 70 % had obtained a clinical response rate. These patient-reported outcomes are hi

SERSTECH AB: Half-year report 1 January – 30 June 201920.8.2019 08:45:00 CESTPress release

SALES INCREASE BY 200% FROM HIGHER MARKET ACCEPTANCE Second quarter 2019 Period 1 January - 30 June 2019 • Net sales: KSEK 5 089 (1 558, +227%) • Net sales: KSEK 8 340 (2 768, +201%) • Profit for the period: KSEK -3 349 (-2 166) • Profit for the period KSEK -7 008 (-5 599) • Earnings per share SEK -0,05 (-0,03) • Earnings per share: SEK -0,11 (-0,09) During Q2, we passed another set of important milestones on our way to becoming a significant player in the security industry and a more mature, professional organization. Our net sales numbers continued to move in the right direction, +227% compared to Q2 2018, and we received significant orders, expanded the reach of our sales network and signed another OEM agreement. We dramatically expanded our R&D capabilities and added dedicated roles for product management and quality assurance, both of which are imperative as our volumes continue to increase. Our operative cash flow continues to improve and for the first half of the year our operat

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso20.8.2019 08:00:00 CESTPress release

Metso Corporation, Stock exchange release on August 20, 2019, at 9:00 a.m. EEST Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso Metso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the holding of mutual funds managed by BlackRock, Inc. of the total amount of shares and financial instruments entitling to shares of Metso. On August 16, 2019, BlackRock Inc.'s direct holding in Metso shares and in financial instruments entitling to shares fell below the 5 percent threshold. On August 14, 2019, BlackRock, Inc.'s total position in Metso amounted to less than 5 percent of Metso’s shares and votes. Metso’s total number of shares and votes is 150,348,256. BlackRock, Inc.’s holdings according to the notification: % of shares and voting rights (A) % of shares and voting rights through financial instruments (B) Total of both in % (A + B) Res

Intention to list & Company Description20.8.2019 08:00:00 CESTPress release

GG St. Kongensgade 100 og 106 P/S Nasdaq First North, Copenhagen, Bond Market Ticker: GGSTK; ISIN: DK0030444401 For release: 20 August 2019 Intention to list the company’s floating rate (7%) secured bond loan 2019/2020 and company description The Director of GG St. Kongensgade 100 og 106 P/S announces that the Company intends to list its floating rate 7% secured bond loan 2019/2020 for trading on Nasdaq First North, Copenhagen. In connection with this, the Company has prepared a Company Description which has been approved by Nasdaq Copenhagen A/S. A copy of the Company Description accompanies this release and it may also be downloaded from the Investor Relations section of the Company’s website at www.gefiongroup.com The Company anticipates the first day of trading in its Bonds being 23 August 2019. GG St. Kongensgade 100 og 106 P/S, incorporated under the laws of Denmark with business registration number 38 30 68 47, having its registered office at c/o Gefion Group A/S, Østergade 1, 2